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Summary
A cross-sectional study was performed in the Netherlands recessive and sporadic cases were indistinguishable from
to the characteristics of the various those o f  the autosomal dominant patients, calf
subtypes within the broad and heterogeneous entity of limb hypertrophy was seen more frequently, and the course of the
girdle muscular dystrophy (LGMD). An attempt was made disease was more severe in autosomal recessive and sporadic
to include all known cases of LGMD in the Netherlands. Out cases. The pectoralis, iliopsoas and gluteal muscles,
of the reported 200 patients, 105 who strictly adductors and hamstrings were the most affected muscles.
criteria were Included, Forty-nine patients, mostly Distal muscle involvement occurred late in the course of 
suffering from dystrophinopathies and facioscapulohumeral the disease. Facial weakness was a rare phenomenon. The
muscular dystrophy, appeared to he misdiagnosed. Thirty- severity o f  the picture was correlated with a
four cases were sporadic, 42 patients came from autosomal deteriorating lung function. All autosomal
recessive and 29 from autosomal dominant families. The inherited cases showed a mild course, although in two
estimated prevalence of LGMD in the Netherlands was at families life-expectancy was reduced because of concomitant 
least H. l X/ 0 (\ The clinical features of the autosomal cardiac involvement,
Keywords: limb girdle muscular dystrophy; prevalence; a-sareoglycan; linkage analysis
Abbreviations: CK = creatine kinase; FSHD =  facioscapulohumeral dystrophy; FVC =  forced vital capacity; LGMD 
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Introduction
Limb girdle muscular dystrophy has long been a controversial variability as regards the age of onset and the course ol the 
entity (Bradley, 1979; Ten Houten, 1979; Walton and Gardner- disease was noted. In some patients secondary a-sarcoglycan
Medwin, 1981; Shields, 1994). After careful exclusion of all 
possible genetically and clinically different diseases which
weakness
LGMD
1994). Recent linkage studies demonstrated an association 
between LGMD and various chromosomal loci (Beckmann 
et a l ,  1991; Ben Othmane et al., 1992; Speer et a i,  1992; 
Bashir et al., 1994; Roberds et al., 1994; Passos-Bueno, 
1996) and thereby reaffirmed the existence of LGMD. Partial 
or complete deficiency of various dystrophin-associated 
proteins has been demonstrated in patients with autosomal 
recessive muscular dystrophy, both as a primary feature and 
as a secondary event (Azibi et al., 1993; Roberds et al., 
1994; Bônneman et al., 1995; Lim et al., 1995; Noguchi 
et al., 1995; Worton, 1995). On a recent workshop, a proposal 
for a new nomenclature based on gene search results has 
been made (Bushby and Beckmann, 1995).
LGMD1 designates chromosome 5q-linked autosomal 
dominant LGMD as described by Gilchrist. Characteristics 
of this phenotype are late-onset limb girdle weakness, 
dysarthria and facial weakness (Gilchrist et al., 1988; Speer 
et a l,  1992). Other chromosomal localizations for autosomal 
dominantly inherited LGMD are as yet unknown. There is 
mostly a relatively benign course (De Coster et al., 1974; 
Bethlem and Wijngaarden, 1976; Chutkow et al., 1986; 
Gilchrist and Leshner, 1986; Marconi et al., 1991; Somer 
et al., 1991).
*
LGMD2A denotes the chromosome 15q-linked autosomal 
recessive disorder encountered in families on Reunion Island 
(Beckmann et a l,  1991). Subsequently several different 
mutations have been identified in the gene encoding for 
the proteolytic enzyme calpain 3 (Richard et a i,  1995). In 
the Amish population, linkage to chromosome 15 has also 
been found in affected families in northern Indiana, first 
described by Jackson (Jackson and Carey, 1961; Jackson and 
Strehler, 1968), whereas in the southern Indiana families 
linkage was excluded (Young et al, 1992; Allamand et al,
«
1995). The phenotype of the chromosome 15 linked form 
shows childhood onset progressive limb girdle weakness 
without calf hypertrophy (Fardeau et al, 1996).
LGMD2B refers to the chromosome 2pl3.3-linked subtype
onset mostly after the age of 15 years and usually shows 
slow progression.
Another subset of patients with autosomal recessive 
inheritance, early onset and rapid progression, known as 
Duchenne-like severe childhood autosomal recessive
deficiency has been demonstrated (Azibi et al., 1993).
Recently the gene encoding the dystrophin-associated 
glycoprotein y-dystroglycan (35DAG) has been mapped to 
13ql2, and mutations in this gene were found (Noguchi 
et a l,  1995).
Limb girdle muscular dystrophy with primary a- 
sarcoglycan deficiency, previously called SCARMD2, has 
been linked to chromosome 17 and now constitutes LGMD2D 
(Roberds et al., 1994). A variety of mutations has been found 
in families with a broad range of clinical presentations and 
intrafamilial variability, and they may be associated with a 
range of a-sarcoglycan staining patterns (Matsumura et al., 
1992; Fardeau et al., 1993; Roberds et al., 1994; Romero 
et al., 1994; Zatz et a l ,  1994; Hayashi et al., 1995; Kawai 
et a l ,  1995; Passos-Bueno et al., 1995; Ljunggren et a l ,  
1995; Piccolo et a l,  1995).
Limb girdle muscular dystrophy in the old order Amish 
of southern Indiana is linked to markers on chromosome 4q, 
and constitutes LGMD2E. The gene for the (3-sarcoglycan
component of the dystrophin-associated-glycoprotein
complex has been mapped to 4ql2, and has been found to 
be defective in these patients, and in one other patient 
(Bonneman et a l,  1995; Lim et a l ,  1995).
So far, most of our knowledge about LGMD has been 
derived from large families, that have been suitable for 
linkage analysis. Detailed genotype-phenotype correlations 
have not been made as yet, due to extreme variability in 
severity which could be associated with any of the identified 
genetic localizations (Jackson and Carey, 1961; Jackson and 
Strehler, 1968; Ben Hamida et a l ,  1983; Bashir et al.., 1994). 
At present little is known about prevalence rates, and about 
the natural history of the disease.
We undertook a study on a large group of LGMD patients 
collected from all neuromuscular centres in the Netherlands. 
The aims of this cross-sectional study were (i) to estimate 
the prevalence of LGMD in the Netherlands, (ii) to make an 
inventory of the clinical spectrum of LGMD, and (iii) to 
identify factors associated with the severity of the disease.
Methods
(Bashir et a l ,  1994; Passos-Bueno et a l,  1995), that has its Patients
The survey was performed in 1.993 and 1994 on 200 patients 
in whom a tentative diagnosis of LGMD had been made 
between 1980 and 1993. They were recruited from the files 
of all (seven) neuromuscular centres of the university hospitals 
in the Netherlands, and from our national patients’ association
muscular dystrophy (SCARMD1), was first reported from (‘Vereniging Spierziekten Nederland’). Patients were
Tunisia (Ben Hamida et al., 1983). Linkage analysis has evaluated in two stages to determine whether they met our
mapped the gene to the pericentromeric region of the long inclusion and exclusion criteria. In the first stage the records
arm of chromosome 13ql2 (Ben Othmane et al, 1992). This 
form is now called LGMD2C. Marked inter- and intrafamilial
of all patients were reviewed. After this initial selection, 
patients who met our criteria and had given informed consent
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to participate in the study, were personally examined. The home, and all other patients were examined in our hospital,
second selection was based on the results of this clinical The neurological history included questions about the age of
examination and of the review of muscle biopsy specimens. onset, the first symptoms of weakness and progression of the
The inclusion criteria consisted of the following: person of disease to other muscle groups.
either gender with progressive, more or less symmetric limb 
girdle weakness, in whom ancillary investigations [including
Muscle strength was assessed (Kendall et a l , 1971), 
ing the British Medical Research Council scale (Medical
serum creatine kinase (CK) activity, EMG and muscle biopsy] Research Council, 1943). Thirty-three muscle groups were
were compatible with a primary myogenic disorder. Patients examined bilaterally. The facial muscles were graded on a
were excluded if another disorder manifesting with limb girdle three-point scale (0 =  severely affected; 1 = mildly affected; 
weakness was present, including metabolic and inflammatory
myopathies, dystrophinopathies, spinal muscular atrophies, 
congenital myopathies/dystrophies, facioscapulo humeral
2
(0
4
normal). Reflexes were assessed on a five-point scale 
absent; 1 =  diminished; 2 =  normal; 3 =  increased;
== clonus). The presence of contractures in eight joints on 
dystrophy (FSHD), Emery-Dreifuss muscular dystrophy or both sides [shoulders, elbows, wrists, hands (fingerfiexors), 
rigid spine syndrome. Therefore, exclusion criteria were hips, knees and ankles] were graded on a three-point scale.
congenital onset, ptosis or weakness o f external ocular (0 absent; 1 mild; 2 severe). The presence of
muscles, skin rash compatible with dermatomyositis, sensory scoliosis, atrophy and hypertrophy were graded on a two- 
abnormalities, severe facial weakness, distal weakness more point scale (0 =  absent; 1 =  present).
severe than proximal; and the presence o f florid active Seventy-four healthy family members over the age of 18
criteria.
denervation, ragged red fibres or numerous extensive cellular years (who also had given their informed consent), were 
infiltrates on muscle biopsy, or glycogen or fat accumulation examined as well, 
within the muscle fibres. Abnormalities in dystrophin analysis 
of muscle biopsy specimens, deletions or duplications within
the dystrophin gene (Xp21), the presence of Turner karyotype Other investigations
or X-autosome translocations were additional exclusion All patients completed a brief questionnaire focusing on
respiratory symptoms; i.e. breathlessness, fatigue, sleep- 
Seventy-four individuals were excluded during the first related symptoms, and headache upon waking. Forced vital 
evaluation for the following reasons: 11 were deceased; in capacity (FVC) was measured in 84 patients in the sitting 
four insufficient information was available; two lived abroad; position with a hand-held spirometer. It was registered as 
three addresses were unknown; 26 refused to enter the study; a percentage of the normal value related to age, height
and gender.
All patients were assigned a functional grade based on a 
scale designed by Vignos et al. (1963), and modified by 
Brooke et al. (1981). This scale is subdivided in two parts:
asin 28 another diagnosis was made: 11 were 
having dystrophinopathy (10 patients with Becker and one 
manifesting carrier; dystrophin analysis of muscle tissue was 
earned out in 37 patients), one polymyositis, 11 FSHD, one 
spinal muscular atrophy, one autosomal dominantly inherited one for shoulders and arms, varying from 1 =  patients being 
scapulo-ilio-peroneal atrophy with cardiopathy (Jennekens able to fully abduct their arms, to 6 =  loss of useful function 
et a l , 1975), and three congenital myopathies or muscular of arms and hands; and one for hips and legs, varying from
1 ~  patients being able to walk and climb stairs without 
assistance, to 10 =  confinement to bed.
ical investigations, extending to five generations
At the entry o f the study 126 subjects were included. They 
were examined clinically and their muscle biopsies were 
reviewed. A tentative subdivision was made into autosomal of ancestors, were performed in a pilot study that included
recessive, sporadic and autosomal dominant cases. Autosomal 
recessive inheritance was considered likely when con­
sanguinity was proven or when more than
at least one girl, was present, and the
the first 15 families, excluding those with autosomal dominant
ritance,
i n s in which, on the basis of family history, 
consanguinity was suspected. Serum CK activity was assessed
ents were healthy. Sporadic cases might be either in all patients and in the majority of their parents and siblings.
Extensive cardiological investigations were performed inautosomal recessive or new mutations of an autosomal
dominant form. Autosomal dominant inheritance was all patients. These results will be described in a separate paper.
likely when affected persons in two or more 
generations were present, and the possibility of X-linked
Muscle
(M
dystrophinopathy was excluded by means ofXp21 screening, girdle syndrome as mentioned above. They were classified 
and/or dystrophin analysis. as either myopathic, dystrophic or neurogenic. Myopathic
changes consisted of variation in muscle fibre size, an increase
in the number of with internal nuclei and
Neurological evaluation splitting. Dystrophic changes included myopathic changes in
The patients were examined by one of the authors (A.J.K.) combination with degenerating and/or regenerating fibres, 
using a standardized protocol. Seven patients were seen at Neurogenic changes comprised tlie presence of small angular
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fibres, staining darkly with oxidative enzymes and non­
specific esterase, or the presence of fibre-type grouping. 
Immunohistochemical analysis of a-sarcoglycan was 
performed in 34 available frozen biopsy specimens.
of neurogenic muscle biopsy changes another two patients 
were diaignosed as having spinal muscular atrophy and 
therefore excluded (this diagnosis was affirmed by DNA 
analysis showing deletions on the spinal muscular atrophy
Obligatory additional ancillary investigations consisted of locus on chromosome 5).
chromosomal analysis including karyotyping in all sporadic Finally, 105 patients, all residents of the Netherlands,
female cases, and Xp21 screening in all sporadic cases. Both entered our study for further analysis. Ninety-seven patients
immunohistochemical and immunobiochemical analyses of Morocco
dystrophin in frozen muscle biopsy specimens was performed Turkey, one from Peru and one was of Indian descent. Forty- 
in all sporadic male cases, in all families in which only males two autosomal recessive cases originated from 24 multiplex
were affected, and in the majority of sporadic female patients. or consanguineous families; 34 were sporadic patients; 29
Acid maltase assay and ischaemic forearm test were individuals came from 10 autosomal ant J;
undertaken when history or (reported) muscle biopsy Nineteen family members (12 in the autosomal recessive
abnormalities raised suspicion of a metabolic myopathy.
Statistical analysis
families, and seven in the autosomal dominant families) were 
reported to have the same disorder, but they refused to 
participate in the study. The prevalence was estimated on 
January 1,1993. The number of inhabitants in the Netherlands
We described the relationship between disease duration and at that time was 15 239 182. Therefore, the prevalence of
patterns of muscle weakness in relative frequencies. LGMD
Furthermore we assessed the association between FVC and 15 239 182] individuals, and of the autosomal recessive and
severity of disease in terms of a relative risk with 95% sporadic cases at least to 5.7 X10-6 [(42+34+12)/15 239 182),
confidence limits. Relative risk expresses how much more Genealogical investigations were performed in 19 families,
likely severe disease is among patients with a marked In seven of these, in which the family history was suggestive,
reduction of pulmonary capacity than among patients with a consanguinity was found. In three other families genealogical
normal capacity. Cut-off value for the functional leg score investigations were extended because of common surnames
was 5, because we considered the loss of independent walking in the ancestors in the fifth generation. In all three,
as an important indicator for the progression of the disease. consanguinity was confirmed: in the sixth, sixth and 10th
The same applied to the cut-off value for the functional arm generation, respectively. Although two other families of
score of 2, reflecting the loss of ability to raise the arms Moroccan origin reported consanguinity as 
above the head. The cut-off point for FVC was set at 70% genealogical investigations were available, 
of the normal value.
Linkage analysis
Most families were too small for linkage analysis. Linkage
Clinical characteristics of the patients with
LGMD
analysis was performed in two large autosomal dominant The bar graph (see Fig. 1) shows the distribution of muscle 
families with cardiac involvement to evaluate the possibility weakness at the time of examination. The autosomal recessi ve 
of linkage to chromosome 5q.
Results
and sporadic cases are considered as one group (.sec 
Discussion) and are compared with the autosomal dominant 
patients. The majority of patients had atrophy and weakness 
of the proximal muscles of upper and lower limbs, particularly
The study population comprised 126 patients whose records when symptoms had been present for > 10  years (data not
had met our inclusion and exclusion criteria. After clinical shown). Weakness was most m
examination and reviewing of the muscle biopsy specimens pectoralis, iliopsoas, gluteal, hip adductor, and the hamstring 
during the second evaluation another 21 patients had to be Mild
excluded. In one patient a diagnosis of mitochondrial with a mean disease duration of 23.5 years (range 22-27
myopathy seemed more likely on the basis of ptosis and years). Distal weakness occurred late in the course of the 
external ophthalmoplegia, six were diagnosed as FSHD disease. Wrist
weakness
weakness
DNA analysis in four and supported in one). Three individuals different subtypes.
and toe extensor muscles were the most frequently involved 
distal muscles. No clear distinctions are present between the
were thought to have congenital myopathy, one rigid spine Despite severe weakness, no patient lost hand function nor
syndrome, one Emery-Dreifuss muscular dystrophy, and was bedridden. Long leg braces were used by only one patient.
The knee and biceps jerks disappeared first in most patients,Miyoshi
weakness with distal leg muscles more or to whereas the ankle reflexes were often relatively spared. In 
the same extent affected as the proximal muscles. Because 13 patients, however, ankle jerks disappeared at an early
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Fig. 1 Muscle involvement on 105 LGMD patients. The bar graph shows the distribution of weakness 
at the time of examination. The autosomal recessive and sporadic cases are considered as one group and 
compared with the autosomal dominant patients. AD =  autosomal dominant; AR =  autosomal 
recessive; spor =  sporadic.
stage of the disease. Achilles tendon contractures were and lower limbs. Thirty-three patients developed weakness
observed in 59% of patients with a median disease duration of the distal leg muscles in the course of the disease. In five
of 23 years (range 0-54 years). Scoliosis was present in patients the only affected distal leg muscles were the calves.
26.4% of patients with a median disease duration of 22 years Slight facial weakness was seen in one 22-year-old patient,
(range 4-54 years). who had been wheelchair-dependent for 11 years and required
Eighty-four patients had no respiratory complaints, 11 had assisted ventilation during the night.
Three patients out of 13 in whom a-sarcoglycan screening
slight breathlessness, three experienced continuous breath- Dystrophic changes were seen in all muscle biopsy 
lessness, three had sleep-related problems and four required 
assisted ventilation during the night. The median FVC for
all 84 patients in whom it was measured was 95.0% (range was performed showed a partial deficiency. One was a 19-
16.9-158). The median FVC for wheelchair-bound patients year-old wheelchair-dependent Moroccan girl, the other a
was 68.0% (range 16.9-123.8). Patients with a pronounced 46-year-old Dutch woman who walked until the age of 44
reduction of FVC were more likely to have severely impaired years, and the third a 55-year-old man, who lost the ability
functional arms scores (relative risk =  4.4; 95% confidence to walk at the age of 46 years.
limits: 2.0/8.4) and leg scores (relative risk 
confidence limits: 2.6/13.4).
5.9;
'ases
Subdivision into autosomal recessive, sporadic, 
autosomal dominant cases (see also Table 1)
Autosomal recessive LGMD
In 32 of the 34 cases, weakness was first evident in the 
proximal leg muscles. In 20 of those patients, weakness of 
the shoulder girdle muscles became evident after a median 
disease duration of 10 years (range 1-43 years). In two
Consanguinity was present in three families with sporadic patients, muscle weakness became manifest simultaneously
patients and in eight of the 21 multiplex families. in upper and lower limbs. Late distal leg involvement was
The symptoms started in the proximal leg muscles in 36 present in 20 patients. In one patient the calf muscles were
patients. Weakness of the shoulder girdle and upper arm the only affected distal leg muscles. Facial weakness was
muscles occurred in 20 patients after a median disease not seen. Two patients required assisted ventilation during 
duration of 10 years (range 1-35 years). In six patients,
muscle weakness became manifest simultaneously in upper Dystrophic changes were seen in the muscle biopsies of
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of the patients with LGMD 105)
Autosomal 
recessive total
Sporadic total Autosomal dominant
Total (M + F) Cardiac involvement
Absent Present
Number of patients (M;F) 42 (17;25) 34 (12;22) 29 (12;17)
Median age in years (range) 36 (8-66) 31 (3-65) 39 (30-69)
Median age of onset in years (range) 12 (1-57) 8 (1-33)
♦
12 (3-52)
Median disease duration in years (range) 20 (2-52) 18 (1-58) 23 (0-50)
Number of wheelchair dependent patients 15 12 3
Median age of losing ambulation in years (range) 26 (8-50) 16(11-69) 45 (33-47)
Calf hypertrophy (number of patients) 23 14 5
Achilles tendon contractures (number of patients) 27 20 14
Scoliosis (number of patients) 8 11 5
Median serum CK activity (times normal value) 23.6 (1-720) 21.8 (1-116.3) 5.4 (1-34)
Median FVC* (% of the normal value) 96.6 (29-158) 89.7 (16.9-126.7) 96.5 (48.7-142.1)
14 (4; 10) 
48 (33-69) 
12 (3-52) 
23 (10-43) 
3
45 (33-47) 
3 
9
3
10 (2.6-34)
15 (8;7)
33 (30-61) 
10 (5-38) 
22 (0-50)
0
2
5
2
1.3 (1-8.3)
102.1 (48.7-142.1) 96.1 (59.4-113.6)
'■’'Measured in 84 patients.
29 patients, one showed an end stage myopathy, and in four, 
myopathic changes were present.
Cardiological abnormalities included a variety of 
dysrhythmias and conduction disturbances, such as atrio-
In three of the 21 muscle biopsies stained for a- ventricular block and bradycardia. In some, cardiological
sarcoglycan, this protein was found to be completely absent. involvement gave rise to syncopal attacks and even sudden
One girl, aged 17 years, had been wheelchair-dependent for cardiac death.
3 years, and the other two, aged 10 and 27 years, were barely
able to walk independently.
Congestive cardiomyopathy was present in two individuals. 
Chromosomal linkage studies excluded the locus on 
chromosome 5q (these data will be the subject of a
Autosomal dominant LGMD
On the basis of the results of a cardiological investigation, a
separate paper).
clear distinction between autosomal dominant families with Family members
and without cardiac involvement emerged. In the autosomal recessive families 20 additional family 
members, and 33 family members of the sporadic cases were
Autosomal dominant LGMD without cardiac examined, but no muscle weakness was found. Serum CK
involvement. This group consisted of 14 individuals activity, estimated in 36 individuals, was normal in 31. Five
from eight families. Weakness stalled in the proximal had a slightly raised serum CK activity ranging from 1.2 to
muscles of the legs in 13 patients, the shoulder girdle and 1.8 times the upper limit.
proximal upper limb muscles being affected in 10 patients Examination of 21 additional family members of the
after a median disease duration of 13 years (range 5-36 autosomal dominant cases yielded three individuals who were
years). In one patient, the shoulder and pelvic girdle muscles presumed to have the disorder because they complained of
were simultaneously involved. Seven patients showed distal decreased muscle strength, and because of the presence of a
leg muscle weakness. Slight facial muscle weakness was slightly elevated serum CK activity (1.2 to 2.5 times the
seen in one patient. upper limit), although there was no muscle weakness. The
Dystrophic muscle biopsies were seen in 12 patients, and serum CK activity of the other 18 family members was
two patients showed myopathic changes.
Autosomal dominant LGMD with cardiac
normal, except for one individual who had a slightly elevated 
serum CK activity (1.2 times the upper limit).
involvement. This group consisted of 15 patients from
due to muscle weakness Discussion
of the proximal legs. In three patients, shoulder and proximal In this cross-sectional study we have attempted to include 
arm muscles became affected as well after a median disease all known cases of 
duration of 21 years (range 10-25 years). Distal lee weakness oatients were renoi
LGMD
LGMD
was observed in seven patients. Slight facial muscle weakness After subjecting the records of all patients to clearly defined
was seen in two. Seven patients had very mild contractures inclusion and exclusion criteria, 126 patients remained. These 
of their elbows.
Four patients showed dystrophic muscle biopsy changes.
individuals were examined clinically, and their muscle biopsy 
specimens were reviewed. After this second screening,
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another 21 patients had to be excluded, leaving only 105 (median 5.4 times the upper limit of normal) were lower
patients for further sis. Therefore, we stress the than those of the autosomal recessive cases (median value
importance of thorough investigations to rule out other 23.6 times the upper limit of normal), which is line with the 
diseases before accepting a diagnosis of LGMD. The literature (Bushby, 1994).
introduction of new techniques such as dystrophin analysis, Awaiting the results of direct mutation analysis and further
and Xp21, chromosome 4q and chromosome 5 screening are immunostaining of the available muscle biopsies in our
extremely helpful to exclude dystrophinopathies, FSHD and patients, we tried to make a distinction between the different
spinal muscular atrophy, respectively. A total of 28 patients phenotypes, 
suffering from these conditions were initially misdiagnosed Sixteen patients of our autosomal recessive group strongly
as LGMD. resembled the Tunisian in linkage to
In a world survey of population frequencies (Emery, 1991), chromosome 13 was found (LGMD2C). They all showed the
the prevalence and incidence rates for mainly adult onset features described by Ben Hamida et al. (1983), i.e. onset of
cases of LGMD were estimated at 20 -40X10”6. In a study their disease before the age o f 13 years, severe progression
by Yates and Emery (1985) the prevalence of adult onset leading to wheelchair-dependency before the age of 31
cases was 7X10-6 at the most. Because o f our well-defined years, marked rise of serum CK activity, almost consistent
diagnostic criteria and the demographic advantages of the hypertrophy of the calves and dystrophic muscle biopsy
Netherlands for ascertaining the majority of LGMD cases, changes. Five out of 16 originated from consanguineous
probably a more reliable prevalence could be established. In 
our study the prevalence of cases with childhood and adult
Moroccan marriages.
patients might the of the
onset was at least 8. I X  10~6, which is lower than previously chromosome 15 linked LGMD2A (Jackson and Carey, 1961;
reported. We presume that the previously mentioned Jackson and Strehler, 1968; Beckmann et a l , 1991; Young
prevalence rates have been artificially inflated by a number et a l ,  1992; Fardeau et al., 1996), in which the following
of neurogenic and myopathic disorders with a limb girdle characteristics were found: age of onset between 3 and 30
distribution of weakness mimicking LGMD. On the other years of age (predominantly childhood onset) with quite a
hand, our prevalence rate may be an underestimate because variable age of confinement to a wheelchair, dystrophic
our study comprised a larger number of females than males, changes on muscle biopsy and gross abnormalities of serum
and presumably a number of male LGMD patients in the enzymes particularly in the early stages. Since shoulder and
files of the neuromuscular centres, in whom no dystrophin pelvic girdle muscles were reported to be affected to the
analysis has been performed, have been 
Duchenne or Becker muscular dystrophy.
as same extent (Jackson and Carey, 1961; Jackson and Strehler, 
1968, Fardeau et ctl., 1996), especially the patients in our 
study, who had had simultaneous onset of weakness inAlthough it has been reported that in LGMD weakness 
may begin in either upper or lower limb muscles (Walton, shoulder and hip girdle muscles, might fit into this category.
1993; Bushby, 1994), in our patients weakness started either The distinction between LGMD2A and LGMD2C
in the proximal leg muscles or simultaneously in upper and however, is difficult to make because interfamilial variability 
lower limbs. All patients reported to have onset of weakness is frequent, and there is considerable overlap.
The clinical picture of the two families with onset in the 
late teens and relatively slow progression, in which recently 
weakness, only slightly elevated serum CK activities, or a linkage to chromosome 2 was found (LGMD2B) (Bashir
in the shoulder girdle muscles were diagnosed as FSHD, 
because they had either
family consistent with dominant et al., 1994), has not been described in detail yet. Distal
inheritance. In two of our patients with scapular onset limb (Miyoshi) myopathy, with onset of muscle weakness in the
girdle weakness, in whom a diagnosis of FSHD was proven 
by DNA analysis, only a trace o f facial was
muscles, has been reported to be
í locus (Bejaoui et al * *
The
occurring in a late stage
patients res
the ’  i *  t \  V  f a
in a ree
CT scanning of
of
scapular onset muscular dystrophy without apparent 
involvement that had possible allelism with FSHD 
(Jardine et al., 1994).
Forty-two patients came from autosomal recessive families,
early involvement 
s and the hamstring
I
I«i
autosomal recessive patients had limb girdle
and atrophyi n  í
muscles. This is a remarkable finding since calf muscles are
34 cases were sporadic and 29 were autosomal dominant usually among the most s in
(Walton and Gar
Most of the sporadic cases'■'SC!--
nearly
cases. The clinical features of the 
including the distribution of weakness, the presence of 
contractures and reflexes, were indistinguishable. Only calf 
hypertrophy was more frequently seen in autosomal recessive 
and sporadic cases. Likewise, the clinical picture was more value, and calf 
severe as compared with the autosomal dominant cases. Genealogical investigations in these particular
aitosomal 
s had serum CK
ictivities that were more than 10 times the normal 
was frequently
Serum CK activities in our autosomal dominant families not seem very in our sanguinity
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could only be confirmed in families in which it was already In keeping with the literature, progression of the disease was 
suspected. The same considerations concerning classification usually mild in our patients. Only three became wheelchair- 
as have been made for the autosomal recessive cases can be bound after the age of 30 years. However, in two of our
applied to the sporadic group. Six of the 34 patients had dominant involvement
atypical features. One patient, who became wheelchair- shortened the life-expectancy. To an extent these families
dependent at the age of 16 years, had a slightly elevated resemble autosomal dominant Emery-Dreifuss muscular
serum CK activity throughout all stages of the disease. His dystrophy, but the absence of early contractures and of
muscle biopsy specimen revealed an end stage myopathy. spinal rigidity clearly distinguishes between these disorders.
This patient might resemble the patients of the large Sudanese Therefore, the disorder has been recognized as a new entity
kindred described by Salih et a l  (1983) who had been (Van der Kooi et al., 1996).
suffering from a severe, progressive form of muscular Forced vital capacity decreased with deterioration of the
dystrophy with onset between the ages of 3 and 5 years, with clinical picture. Life expectancy is probably determined by
dystrophic features on muscle biopsy, and a mildly elevated pulmonary function. This implies that, especially in the more
(up to five times the normal value) serum CK activity. Four severely disabled patients, doctors should be aware of the
patients had an only slightly elevated serum CK activity and development of respiratory symptoms. Notably appearance
sole myopathic changes, without degenerating or regenerating of sleep-related problems and continuous breathlessness
fibres, on muscle biopsy. Another patient showed dystrophic necessitate further investigations in order to institute timely
changes, but had an only four times elevated serum CK artificial ventilation, 
activity. The latter five may be de novo mutations of autosomal 
dominant LGMD.
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a-Sarcoglycan deficiency in three autosomal recessive 
cases and absence in three sporadic cases, indicate that 
primary and secondaiy a-sarcoglycan deficiencies are 
encountered in the Netherlands as well. The clinical pictures 
of these patients showed great variation, as is also the case 
in the reported patients (Matsumura et a l,  1992; Azibi et al,
1993; Fardeau et a l,  1993; Roberds et a l,  1994; Romero 
et a l,  1994; Zatz e ta l ,  1994; Hayashi et a l,  1995; Ljunggren 
et a l ,  1995; Passos-Bueno et a l,  1995; Piccolo et a l,  1995).
Autosomal dominantly inherited LGMD was believed to 
be rare (Walton and Nattrass, 1954; Jerusalem and Sieb,
1992). As yet, relatively few families have been described 
with autosomal dominant LGMD, showing a wide range of 
clinical features and histological findings (Schneidermann
et a l,  1969; Bacon and Smith, 1971; De Coster et a l,  1974;
Bethlem and Wijngaarden, 1976; Hastings et a l,  1980;
Chutkow et a l,  1986; Gilchrist et a l,  1988; Marconi et al,
1991; Somer et a l ,  1991; Miller et a l,  1992). In our study, Azibi K, Bachner L, Beckmann JS, Matsumura K, Hamouda E,
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